Describe an asset or provide a ticker. Get a functional Excel model with defensible assumptions. Stress-test assumptions, run scenarios, and do in-depth research, just by chatting with the agent.
Get early access — $20 →
Provide a ticker. The agent pulls the pipeline, builds a model that reverse-engineers the current market cap, and tells you what you'd have to believe to get there.
Reverse-engineer any public biotech valuation.
Easily see which assumptions move the needle, and which assumptions you can tweak while still remaining within industry benchmarks.
See which assumptions move the needle, and which are defensible.
The agent can search the web to research assumptions, and has specific skills for things like calculating pricing and finding approved drugs in an indication.
Automate company research and Excel modeling.
We have built models like this to support public company board discussions, negotiate nine-figure venture investments, and to support investment research memos.
This tool builds those same models, in minutes.
The current tool supports rNPV / DCF valuation of multi-product development-stage biotech companies. It currently cannot modeling licensing / partnering transactions (i.e., it can't model royalties or biobucks) or geography-specific revenues. These features, and many others, will come soon.
Explore the tool with a $20 explorer credit. Your $20 gives you limited usage credits so you can build models, research assumptions, and stress-test valuations.
Explorer credits are available for a limited time only during the early access launch period. Pricing will evolve as the product grows, with options for purchasing more credits, and access to more advanced features as we roll them out (such as licensing and partnership transaction modeling, geography-specific revenue splits, richer research tools, and more).
Get started →